| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Chugai Pharma Technology Taizhou Co. Ltd. | ||||||||
| Chugai Pharma Body Research P.T.E. Limited | ||||||||
| Chugai Pharma Germany GmbH | ||||||||
| Chugai Pharma Europe Limited | ||||||||
| 中外ベンチャー・ファンド・エルエルシー | ||||||||
| 中外製薬ビジネスソリューション株式会社 | ||||||||
| 中外製薬工業株式会社 | ||||||||
| 株式会社中外医科学研究所 | ||||||||
| 株式会社中外臨床研究センター |
Founded in 1925, the company's founding spirit was "to create medicines that serve society."
Chugai Pharmaceutical celebrated its 100th anniversary on March 10, 2025. As part of the commemorative project, the company is promoting the 'My Action Declaration' across the entire group, which embodies employees' 'thoughts' and marks a step into the future.
Chugai Pharmaceutical, which celebrated its 100th anniversary on March 10, 2025, is promoting the 'My Action Declaration' across the entire group, embodying employees' 'thoughts' and marking a step into the future. The 'My Action Declaration' aligns the company's 100-year history with employees' 'stories' and encourages future actions.
Chugai Pharmaceutical, which celebrated its 100th anniversary on March 10, 2025, held a 'Founding 100th Anniversary Ceremony' in May of the same year. The ceremony was attended by 252 guests from Japan and abroad who support the company daily, providing a valuable opportunity to reflect on the past 100 years and renew commitments for the next century.
The research base of Chugai Pharmaceutical, 'Chugai Life Science Park Yokohama,' is surrounded by lush greenery in Totsuka Ward, Yokohama City. Two original monuments, 'Life Science Code | Memory of Life Science' and 'Life Science Summit | The Peak of Life Science,' standing at the entrance, have received numerous international design awards. This time, the monuments that commemorate the memory of life science received a global design award.
Engraving the memory of life science — The monuments at 'Chugai Life Science Park Yokohama' have won international design awards.
#Co-creation
On November 27 (Thursday) and 28 (Friday), 2025, the business conference 'CHUGAI INNOVATION DAY 2025' was held at the Maru Building Hall & Conference Square in Marunouchi, Tokyo.
Chugai Pharmaceutical Co., Ltd. received the "IR Excellence Award 2026" "IR Excellence Award Grand Prize" hosted by the Japan IR Council. The company was selected for the Grand Prize for the first time, following its previous wins of the award in 2020 and 2023.
Core sales revenue was ¥1.1681 trillion (17.2% YoY increase), Core operating profit was ¥536.1 billion (19.0% increase), and Core quarterly profit was ¥384.7 billion (20.2% increase), resulting in revenue and profit growth. We expect to exceed the full-year forecast. Sales of finished products increased due to exports of NEMLUVIO and Alesensa, growth in domestic flagship and new products, and other sales revenue also increased due to royalty income and one-time payments.
Roche announced on October 25, 2026 at ESMO the results of the Phase III clinical trial (Krascendo1) of the KRAS G12C inhibitor divarasib, targeting pre‑treated KRAS G12C mutation‑positive non‑small cell lung cancer. The results demonstrate best‑in‑class efficacy and are reported to contribute to the advancement of treatment standards. For details, please refer to Roche's media release.
Chugai Pharmaceutical announced that Roche on October 23 presented the detailed interim analysis data of the Phase III IMAgINATION trial of Seafaxelcen Sodium for IgA nephropathy at the American Society of Nephrology (ASN) Kidney Week 2026. They directed readers to refer to Roche's media release for details.
F. Hoffmann-La Roche announced its sales results for January through September 2026. The announcement was posted on the company’s website and is included in the Roche Group’s results. The contact is the Head of Public Relations and Investor Relations at Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical announced that Roche has obtained FDA approval in the United States for Enspirit (generic name: satralizumab) for thyroid eye disease. Details are provided in Roche's media release.
Chugai Pharmaceutical received the 2026 Porter Prize, hosted by Hitotsubashi University Graduate School, for the first time. It was recognized for its distinctive drug discovery driven by technology; its use of antibody engineering and mid-molecule drug discovery technologies; and its business model, based on a strategic alliance with Roche, and high profitability. This is the first time a pharmaceutical company has received the award in 19 years, since fiscal 2007.
Roche announced one-year data from the Phase III MEERKAT and SANDCAT trials targeting macular edema associated with non‑infectious uveitis. In both trials, improvements in vision and macular edema were maintained up to week 52, and Bamikibart demonstrated a consistent safety profile through week 52. Approximately two‑thirds of patients who transitioned to an as‑needed dosing period after week 16 required no additional dosing, and most patients who received additional dosing had only one dose.
Chugai Pharmaceutical will establish Chugai Pharmaceutical Korea Co., Ltd. in preparation for launching new drugs in South Korea. The new subsidiary is scheduled to be registered on November 2, 2026, and will gradually pursue marketing approvals and build its own sales organization. The Korean market is expected to grow as the population ages and access to innovative medicines improves. As its pipeline expands, Chugai plans to establish a structure that handles approvals and sales directly.
Chugai Pharmaceutical Co., Ltd. signed a global licensing agreement with InxMed for SPYK04, a RAF-MEK molecular glue for treating solid tumors. Under the agreement, InxMed will have exclusive rights to develop, manufacture, and sell SPYK04, and will pay an upfront fee and royalties based on sales.